MXPA03006412A - Metodos para administrar analogos de epotilona para tratamiento de cancer. - Google Patents
Metodos para administrar analogos de epotilona para tratamiento de cancer.Info
- Publication number
- MXPA03006412A MXPA03006412A MXPA03006412A MXPA03006412A MXPA03006412A MX PA03006412 A MXPA03006412 A MX PA03006412A MX PA03006412 A MXPA03006412 A MX PA03006412A MX PA03006412 A MXPA03006412 A MX PA03006412A MX PA03006412 A MXPA03006412 A MX PA03006412A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- methods
- epothilone analogs
- administering epothilone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26422801P | 2001-01-25 | 2001-01-25 | |
| US29000601P | 2001-05-11 | 2001-05-11 | |
| PCT/US2002/001813 WO2002058700A1 (en) | 2001-01-25 | 2002-01-22 | Methods of administering epothilone analogs for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03006412A true MXPA03006412A (es) | 2003-10-15 |
Family
ID=26950348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03006412A MXPA03006412A (es) | 2001-01-25 | 2002-01-22 | Metodos para administrar analogos de epotilona para tratamiento de cancer. |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JP4633331B2 (no) |
| AU (1) | AU2002245296B2 (no) |
| CA (1) | CA2434526C (no) |
| HR (1) | HRP20030677B1 (no) |
| IL (1) | IL156578A0 (no) |
| MX (1) | MXPA03006412A (no) |
| NO (1) | NO335119B1 (no) |
| PL (1) | PL207720B1 (no) |
| RU (1) | RU2292202C2 (no) |
| WO (1) | WO2002058700A1 (no) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| JP4579351B2 (ja) | 1996-12-03 | 2010-11-10 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | エポチロンの合成とその中間体及びその類似物並びにその使用 |
| US8618085B2 (en) * | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
| NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| AU2008200555C1 (en) * | 2003-03-14 | 2011-12-15 | Novartis Ag | Treatment of proliferative diseases with epothilone derivatives and radiation |
| GB0305928D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| EP1674098A1 (en) * | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| SI3002009T1 (sl) * | 2007-06-01 | 2021-09-30 | Wyeth Llc | Zdravljenje kronične mieloične levkemije, ki je odporna na imatinib, ki ima mutacijo 1457t>c na genu bcrabl, s pomočjo sestavine bosutinib |
| WO2009089138A1 (en) * | 2008-01-04 | 2009-07-16 | Bristol-Myers Squibb Company | Oral administration of ixabepilone |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
| US5681846A (en) * | 1995-03-17 | 1997-10-28 | Board Of Regents, The University Of Texas System | Extended stability formulations for paclitaxel |
| JP4579351B2 (ja) * | 1996-12-03 | 2010-11-10 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | エポチロンの合成とその中間体及びその類似物並びにその使用 |
| US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| WO1999004330A1 (en) * | 1997-07-18 | 1999-01-28 | Hewlett-Packard Company | Format for passing information between devices |
| US6365749B1 (en) * | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| MY125921A (en) * | 1998-02-05 | 2006-08-30 | Novartis Ag | Compositions containing organic compounds |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6399638B1 (en) * | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| EE200100431A (et) * | 1999-02-18 | 2002-12-16 | Schering Aktiengesellschaft | 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine |
| UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
-
2002
- 2002-01-22 PL PL373727A patent/PL207720B1/pl unknown
- 2002-01-22 WO PCT/US2002/001813 patent/WO2002058700A1/en active IP Right Grant
- 2002-01-22 RU RU2003126170/15A patent/RU2292202C2/ru active
- 2002-01-22 CA CA2434526A patent/CA2434526C/en not_active Expired - Lifetime
- 2002-01-22 IL IL15657802A patent/IL156578A0/xx not_active IP Right Cessation
- 2002-01-22 JP JP2002559034A patent/JP4633331B2/ja not_active Expired - Fee Related
- 2002-01-22 MX MXPA03006412A patent/MXPA03006412A/es active IP Right Grant
- 2002-01-22 AU AU2002245296A patent/AU2002245296B2/en not_active Ceased
-
2003
- 2003-07-24 NO NO20033341A patent/NO335119B1/no not_active IP Right Cessation
- 2003-08-25 HR HR20030677A patent/HRP20030677B1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2434526A1 (en) | 2002-08-01 |
| HRP20030677A2 (en) | 2004-08-31 |
| RU2292202C2 (ru) | 2007-01-27 |
| NO335119B1 (no) | 2014-09-22 |
| JP4633331B2 (ja) | 2011-02-16 |
| RU2003126170A (ru) | 2005-02-27 |
| IL156578A0 (en) | 2004-01-04 |
| PL373727A1 (en) | 2005-09-05 |
| AU2002245296B2 (en) | 2006-12-21 |
| PL207720B1 (pl) | 2011-01-31 |
| HRP20030677B1 (en) | 2011-10-31 |
| WO2002058700A1 (en) | 2002-08-01 |
| NO20033341D0 (no) | 2003-07-24 |
| CA2434526C (en) | 2011-11-01 |
| NO20033341L (no) | 2003-09-04 |
| JP2005503323A (ja) | 2005-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200305126B (en) | Methods of administering epothilone analogs for the treatment of cancer. | |
| HK1116339A1 (en) | Methods of administering epothilone analogs for the treatment of cancer | |
| IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
| PL375532A1 (en) | Benzimidazol-1-yl-thiophene compounds for the treatment of cancer | |
| IL160884A0 (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| IL159344A0 (en) | Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease | |
| HUP0400314A3 (en) | Pharmaceutical combinations for the treatment of cancer | |
| IL164599A0 (en) | Combination therapy for the treatment of cancer | |
| HK1072443A1 (en) | Immunoconjugates for the treatment of tumours | |
| HK1097410A1 (en) | Analogs of benzoquinone-containing ansamycins for the treatment of cancer | |
| EP1613308A4 (en) | CANCER TREATMENT METHODS | |
| EP1390029A4 (en) | PHENYLINDOLES FOR THE TREATMENT OF HIV INFECTION | |
| IL159887A0 (en) | Combination therapy for the treatment of cancer | |
| MXPA03007423A (es) | Derivados de epotilona para tratamiento de tumores refractarios. | |
| MXPA03007394A (es) | Tratamiento de tumores refractarios mediante uso de derivados de epotilona. | |
| EP1442062A4 (en) | METHOD FOR TREATING CARCINOMA | |
| EP1545510A4 (en) | SUBSTITUTED PHENYLINDOLE FOR THE TREATMENT OF HIV | |
| HK1051692A1 (en) | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain. | |
| MXPA03006412A (es) | Metodos para administrar analogos de epotilona para tratamiento de cancer. | |
| EP1461030A4 (en) | AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | |
| IL162818A0 (en) | Combination therapy for the treatment of bacterialinfections | |
| LT1496918T (lt) | Natrio meta-arsenito naudojimas navikams gydyti | |
| MXPA03003032A (es) | Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos. | |
| AU2002304883A1 (en) | Device for the treatment of tumours | |
| AU2000263936A1 (en) | Substance p analogs for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |